Thoracic aortic aneurysm

Illuminate Announces Results of New Live Saving Thoracic Aortic Aneurysm Surveillance Program

Retrieved on: 
Tuesday, February 20, 2024
Thoracic aortic aneurysm, TAA, Vascular surgery, Discovery, Risk, Society, UC, University of California, Davis, Health, Patient, AAA, Illuminate, Leakage, Abdominal aortic aneurysm, Medical device

OVERLAND PARK, Kan., Feb. 20, 2024 /PRNewswire/ -- Softek Illuminate, Inc., provider of enterprise follow-up management and discovery software, and UC Davis Health have developed a centralized Thoracic Aortic Aneurysm (TAA) surveillance program that is saving lives. The effort has identified at-risk patients who may have been 'lost-to-follow-up' because they missed care due to numerous factors.

Key Points: 
  • OVERLAND PARK, Kan., Feb. 20, 2024 /PRNewswire/ -- Softek Illuminate, Inc. , provider of enterprise follow-up management and discovery software, and UC Davis Health have developed a centralized Thoracic Aortic Aneurysm (TAA) surveillance program that is saving lives.
  • This new program builds on the previously announced success between Illuminate and UC Davis Health with a centralized Abdominal Aortic Aneurysm (AAA) program.
  • This new TAA program will further advance efforts to make it easier for care navigators to manage vascular patients with critical follow-up care requirements.
  • Their participation can lower the barrier for implementing a comprehensive aneurysm surveillance program and ensure the following benefits are realized:
    Align follow-up care with health system care guidelines.

Jefferson Welcomes Internationally Recognized Cardiovascular Surgeon, Joseph E. Bavaria, MD to Enhance Heart and Vascular Program

Retrieved on: 
Wednesday, November 15, 2023
Thoracic aortic aneurysm, Jefferson Health, MPP, Tulane University, FACP, Society of Thoracic Surgeons, Interim, Cardiothoracic surgery, STS, Heart, Surgeon, EACTS, Hospital, Medicine, Thomas Jefferson University, Division, Master of Science, University, Diagnosis, Doctor of Philosophy, Society, Dentistry, MD

PHILADELPHIA, Nov. 15, 2023 /PRNewswire/ -- Jefferson is pleased to announce that Joseph E. Bavaria, MD is joining Jefferson Health and Sidney Kimmel Medical College, effective January 15, 2024.

Key Points: 
  • PHILADELPHIA, Nov. 15, 2023 /PRNewswire/ -- Jefferson is pleased to announce that Joseph E. Bavaria, MD is joining Jefferson Health and Sidney Kimmel Medical College, effective January 15, 2024.
  • Dr. Bavaria brings a wealth of leadership and surgical expertise to Jefferson's expanding team as it continues to advance the diagnosis, treatment and prevention of heart and vascular conditions.
  • "Dr. Bavaria's distinguished career in cardiovascular research and surgical advancements make him a valuable addition to Jefferson's expanding Heart and Vascular program," said Baligh Yehia, MD, MPP, MSc, FACP, President of Jefferson Health.
  • "This is a unique time to be joining Jefferson as the organization focuses on integrating cardiovascular services throughout the system.

ConcertAI's TeraRecon Broadens Collaboration with Avicenna.AI to Offer AI-Driven Care Coordination for Pulmonary Embolism and Aortic Disease

Retrieved on: 
Wednesday, November 1, 2023
FDA, Intelligence, Triage, AD, Radiology, PACS, AAA, Rupture, Health, Cardiology, Pulmonary embolism, Thoracic aortic aneurysm, Abdominal aortic aneurysm, PE, TAA, Machine learning, Neurology, Aortic dissection, CINA, Algorithm, Avicenna, Deep learning, Patient, Stenosis, Medical device, EU

Together, they will provide global solutions that leverage artificial intelligence to enhance care coordination and improve patient triage for individuals afflicted with pulmonary embolism (PE) and aortic dissection (AD).

Key Points: 
  • Together, they will provide global solutions that leverage artificial intelligence to enhance care coordination and improve patient triage for individuals afflicted with pulmonary embolism (PE) and aortic dissection (AD).
  • This collaboration aims to expedite clinical decision-making and optimize patient care for these critical medical conditions.
  • "We are excited to empower TeraRecon users worldwide with our groundbreaking AI-driven solutions for the care coordination of pulmonary embolism and aortic dissection," said Cyril Di Grandi, Chief Executive Officer of Avicenna.AI.
  • We eagerly anticipate extending the benefits of our pulmonary embolism and aortic dissection triage tools to the emergency room and beyond."

Aquedeon Medical, Inc. Receives FDA IDE Approval for the Duett Vascular Graft System

Retrieved on: 
Wednesday, August 23, 2023
Surgeon, University, Clinical trial, Federal, Thoracic aortic aneurysm, Social Democratic Federation (United States), Penn Presbyterian Medical Center, Cardiopulmonary bypass, Silicon, Patient, Cardiac surgery, Risk, Principal, IDE, FDA, Dentistry

The procedure often requires 30-45 minutes of surgical time to complete anastomoses where the cardiothoracic surgeon sutures each individual native branch vessel to the surgical graft.

Key Points: 
  • The procedure often requires 30-45 minutes of surgical time to complete anastomoses where the cardiothoracic surgeon sutures each individual native branch vessel to the surgical graft.
  • The Duett Vascular Graft System was uniquely designed to standardize and simplify open surgical thoracic aortic procedures with the goal of providing cardiothoracic surgeons a means to treat the target vessels effectively and efficiently.
  • Dr. Szeto also highlighted his longstanding involvement with the Duett Vascular Graft System's evolution, since the company's inception, and expressed enthusiasm about participating in the imminent clinical trial.
  • "The Duett Vascular Graft System has been developed in collaboration with leading cardiothoracic surgeon and the device is aimed at helping to address the complexities and intricacies of thoracic aortic surgeries.

Statement on Aortic Aneurysm Reflecting on the Death of Grant Wahl

Retrieved on: 
Wednesday, December 14, 2022
Ehlers–Danlos syndromes, Heart, CT, Degenerative disease, MD, Cardiology, Marfan syndrome, American Heart Association, American College, Life, Diagnosis, Skin, The Marfan Foundation, Washington University School of Medicine, MRI, Blood, Thoracic aortic aneurysm, Science, 2009 Davis Cup, Friends, Dissection, American College of Cardiology, Death, Wahl, Aortic aneurysm, Barnes-Jewish Hospital, Family, Nonsyndromic deafness, Intelligence, Child, Aneurysm, Woman, Multimedia, TAA, Microdeletion syndrome, Education, Pain scale, RENT, Connective tissue, Genetic testing, Joint, Blood vessel, Nervous system, Risk, Medical device, Pharmaceutical industry, Hospital

NEW YORK, Dec. 14, 2022 /PRNewswire/ -- The Marfan Foundation is saddened to learn that journalist Grant Wahl has died due to complications of an ascending thoracic aortic aneurysm.  Diagnosed, this condition can be treated if people and their health professionals know the risk and manageable complications.

Key Points: 
  • NEW YORK, Dec. 14, 2022 /PRNewswire/ -- The Marfan Foundation is saddened to learn that journalist Grant Wahl has died due to complications of an ascending thoracic aortic aneurysm.
  • We commit to continued investment in science, patient support, and collaborative efforts that will make these tragic moments fewer and fewer.
  • Recently, the American Heart Association and American College of Cardiology published new guidelines for identifying and treating aortic disease.
  • The Foundation, established more than 40 years ago, has been the leading advocate for aortic disease awareness and education since the death of Jonathan Larson, composer and playwright of RENT, who died of an undiagnosed aortic aneurysm and aortic dissection in 1995.

Aidoc Secures New FDA Clearances Enabling Faster and More Accurate Detection of Critical Neurological and Cardiovascular Conditions

Retrieved on: 
Thursday, November 17, 2022
Triage, AD, LVO, Thoracic aortic aneurysm, EHR, Surgery, Stroke, Length of stay, Mevo, Radiology, Physician, M1, FDA, Doctor Foster, Aidoc, ICA, Computer-aided simple triage, Intelligence, Abdominal aortic aneurysm, Middle cerebral artery, Anterior cerebral artery, Patient, PCA, COVID-19, Pressure, Surgeon, Communication, Basilar artery, Posterior cerebral artery, Brain, Vos, MCA, AI, Vertebral artery, ACA, Ambient occlusion, Yale New Haven Hospital, CT, Medical device, Medicine, Medical imaging, Mevo Modi'im

NEW YORK, Nov. 17, 2022 /PRNewswire/ -- Aidoc, the leading provider of healthcare AI solutions, today announced it has increased its FDA clearances to 11 with the addition of CT-based AI solutions - aortic dissection (AD) and all vessel occlusions (VOs). These clearances continue Aidoc's impressive momentum and leadership in healthcare AI, giving the organization the most FDA clearances in the AI imaging space.

Key Points: 
  • These clearances continue Aidoc's impressive momentum and leadership in healthcare AI, giving the organization the most FDA clearances in the AI imaging space.
  • "Effective healthcare and treatment of acute conditions, like stroke and aortic dissections, require rapid, coordinated care minutes can matter," said Aidoc CEO Elad Walach.
  • Aidoc is the only company with a proven EHR integration for the population of critical, time-sensitive patient information on the app.
  • Aidoc is the leading provider of artificial intelligence healthcare solutions that empower physicians to expedite patient treatment and enhance quality of care.

Global Transcatheter Mitral Valve Implantation (TMVI) Market Report 2022: Analysis and Forecasts, 2015-2021 & 2022-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 7, 2022
Health, Medical Devices, Cardiology, Aortic aneurysm, Forecast model, Country, AAA, Aorta, TAA, Thoracic aortic aneurysm, SWOT, Industry, Review, Region, COVID-19, Market access, Epidemiology, Aneurysm, Medical device, Retail, Healthcare

The "Transcatheter Mitral Valve Implantation (TMVI) (Cardiovascular) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Transcatheter Mitral Valve Implantation (TMVI) (Cardiovascular) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.
  • The model discusses in detail the impact of COVID-19 on Transcatheter Mitral Valve Implantation (TMVI) market for the year 2020 and beyond.
  • Key Inclusions of the market model are:
    Currently marketed Transcatheter Mitral Valve Implantation (TMVI) market and evolving competitive landscape:
    Insightful review of the key industry trends.
  • Annualized total Transcatheter Mitral Valve Implantation (TMVI) market revenue by segment and market outlooks from 2015-2030.

Genomics Testing Companies and Laboratories Combine Efforts to Establish the CardioGenomic Testing Alliance

Retrieved on: 
Tuesday, March 22, 2022
SADS, GeneDx, Precision medicine, Diagnosis, Degenerative disease, Genetic testing, Genetics, Cardiology, Arrhythmia, Thoracic aortic aneurysm, Genomics, American Heart Association, Cardiomyopathy, Laboratory, Epidemiology, CGTA, Awareness, Patient, Pharmaceutical industry, Medical device, Illumina

WASHINGTON, March 22, 2022 /PRNewswire/ -- Several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology. CGTA will inform healthcare providers and other stakeholders to the value of such testing to assure adherence to existing guidelines from professional medical societies, inform medical management and cascade testing, and improve clinical outcomes.

Key Points: 
  • WASHINGTON, March 22, 2022 /PRNewswire/ --Several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology.
  • "The companies forming this coalition believe in extensive clinical utility of cardiogenomic testing.
  • Their combined efforts to increase awareness and utilization of cardiogenomic testing will show the positive outcomes genetic testing can have on patients," says Melissa Dempsey, genetic counselor at Illumina and CGTA chairwoman.
  • Despite evidence and major professional society recommendations, utilization and awareness of cardiogenomic testing remains low.

Global Adult Vaccine Industry Trends and Opportunities, 2022-2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 18, 2022
Biotechnology, Pharmaceutical, Health, Measles, GlaxoSmithKline, DPT vaccine, Bacterial pneumonia, Respiratory system, Hepatitis, Man, Cervical cancer, CDC, Government, Prevalence, Influenza, CSL Limited, Fungus, Rubella, Vaccine, Merck & Co., Death, Baloxavir marboxil, HPV, Adult, Degenerative disease, Shingles, Virus, Billion, Center, Respiratory tract, Chickenpox, Pfizer, MMR, Sanofi Pasteur, USD, Rubella vaccine, Centers for Disease Control and Prevention, Thoracic aortic aneurysm, Research, Mumps, BLA, COVID-19, Travel, Vaccination, TAA, CAGR, Pharmaceutical industry, Growth, Neisseria meningitidis, Pneumonia

The "Global Adult Vaccine Market, Size, Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Adult Vaccine Market, Size, Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Recently, the increasing prevalence of diseases and novel vaccine technologies has been significant drivers for the global adult vaccines market.
  • In addition, increased research in vaccine technologies and increasing government support also support the growth of the global adult vaccines market.
  • According to this report Global Adult Vaccine Industry is projected to grow with a CAGR of 6% from 2021-2027.

Global Pediatric Vaccines Market Forecast 2022-2027, Featuring GlaxoSmithKline, Merck, Pfizer, Sanofi Pasteur and CSL - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 26, 2022
Children, Pharmaceutical, Health, Consumer, COVID-19, USD, Vaccine, CSL Limited, GlaxoSmithKline, Sanofi Pasteur, TAA, Merck & Co., Life, MMR, Vaccination, Infant, Thoracic aortic aneurysm, Immunization, Rotavirus, Hepatitis, Public health, Pfizer, Chickenpox, Global health, CAGR, DPT vaccine, Pharmaceutical industry, Coronavirus, Neisseria meningitidis, Pediatrics, Growth

The "Pediatric Vaccines Market, Share, Global Forecast 2022-2027, Industry Trends, Growth, Size, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pediatric Vaccines Market, Share, Global Forecast 2022-2027, Industry Trends, Growth, Size, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The Global Pediatric Vaccines Market is expected to reach USD 62 Billion in 2027.
  • In this huge market of vaccines Pediatric Vaccines for Coronavirus account for a significant market share.
  • Hence, amidst the pandemic, the global market for Pediatric vaccines declined in 2020 as most healthcare personal were busy in COVID-19 management.